Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35066, first published .
How Vaccine Ambivalence Can Lead People Who Inject Drugs to Decline COVID-19 Vaccination and Ways This Can Be Addressed: Qualitative Study

How Vaccine Ambivalence Can Lead People Who Inject Drugs to Decline COVID-19 Vaccination and Ways This Can Be Addressed: Qualitative Study

How Vaccine Ambivalence Can Lead People Who Inject Drugs to Decline COVID-19 Vaccination and Ways This Can Be Addressed: Qualitative Study

Journals

  1. Yeager S, Abramovitz D, Harvey-Vera A, Vera C, Algarin A, Smith L, Rangel G, Artamonova I, Patterson T, Bazzi A, Brugman E, Strathdee S. A cross-sectional study of factors associated with COVID-19 testing among people who inject drugs: missed opportunities for reaching those most at risk. BMC Public Health 2022;22(1) View
  2. Bazzi A, Harvey-Vera A, Buesig-Stamos T, Abramovitz D, Vera C, Artamonova I, Patterson T, Strathdee S. Study protocol for a pilot randomized controlled trial to increase COVID-19 testing and vaccination among people who inject drugs in San Diego County. Addiction Science & Clinical Practice 2022;17(1) View
  3. Aronson I, Bennett A, Ardouin-Guerrier M, Rivera-Castellar G, Gibson B, Vargas-Estrella B. Using the participatory education and research into lived experience (PEARLE) methodology to localize content and target specific populations. Frontiers in Digital Health 2022;4 View
  4. Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K, Heard S, Maher L. Uptake of COVID-19 vaccination among people who inject drugs. Harm Reduction Journal 2022;19(1) View
  5. Setiyaningrum E, Basuki I, Setyowati S. Development of Curriculum Management Models in the Addiction Science Study Program. IJORER : International Journal of Recent Educational Research 2022;3(4):451 View
  6. Valasek C, Streuli S, Pines H, Mittal M, Strathdee S, Vera C, Harvey-Vera A, Bazzi A. COVID-19 vaccination acceptability and experiences among people who inject drugs in San Diego County. Preventive Medicine Reports 2022;30:101989 View
  7. Krawczyk N, Rivera B, Basaraba C, Corbeil T, Allen B, Schultebraucks K, Henry B, Pincus H, Levin F, Martinez D. COVID‐19 complications among patients with opioid use disorder: a retrospective cohort study across five major NYC hospital systems. Addiction 2023;118(5):857 View
  8. Price O, Maher L, Dietze P, Bruno R, Crawford S, Sutherland R, Salom C, Dore G, Peacock A. COVID‐19 vaccine attitudes and facilitators among people in Australia who inject drugs. Drug and Alcohol Review 2023;42(5):1066 View
  9. Corcorran M, Austin E, Behrends C, Briggs E, Frost M, Juarez A, Frank N, Healy E, Prohaska S, LaKosky P, Kapadia S, Perlman D, Schackman B, Des Jarlais D, Williams E, Glick S. Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 Vaccine. Journal of Addiction Medicine 2023;17(1):e36 View
  10. Lazarus J, Villota-Rivas M, Ryan P, Buti M, Grau-López L, Cuevas G, Espada J, Morón W, Palma-Álvarez R, Feld J, Valencia J. Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain. Communications Medicine 2023;3(1) View
  11. Byrne C, Radley A, Fletcher E, Thain D, Stephens B, Dillon J. A multicomponent holistic care pathway for people who use drugs in Tayside, Scotland. International Journal of Drug Policy 2023;120:104159 View
  12. Murnion B, Carland J, Jefferies M, Au M, Tracy M. ‘It’s a fragile open door’—enhancing COVID-19 vaccination rates in people receiving treatment for substance use disorder. Journal of Public Health 2023;45(4):e729 View
  13. Patel E, Mehta S, Genberg B, Baker O, Schluth C, Astemborski J, Fernandez R, Quinn T, Kirk G, Laeyendecker O. Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in Baltimore, Maryland. Drug and Alcohol Dependence Reports 2023;8:100184 View
  14. Feld J, Bruneau J, Dore G, Ghany M, Hansen B, Sulkowski M, Thomas D. Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations. Clinical Infectious Diseases 2023;77(Supplement_3):S262 View
  15. McAdam E, Hayashi K, Barker B, Reddon H, Choi J, Kerr T, DeBeck K. COVID-19 vaccination among young people who use drugs in Vancouver, Canada. Vaccine 2024;42(4):864 View
  16. Yeung A, Wilkinson M, Bishop J, Taylor B, Palmateer N, Barnsdale L, Lang J, Cameron C, McCormick D, Clusker T, McAuley A, Hutchinson S. SARS-CoV-2 vaccine uptake and risks of severe COVID-19 disease among people prescribed opioid agonist therapy in Scotland. Journal of Epidemiology and Community Health 2024;78(6):380 View
  17. Zovich B, Freeland C, Moore H, Sapp K, Qureshi A, Holbert R, Zambrano J, Bhangoo D, Cohen C, Hass R, Jessop A. Dismantling Barriers to Hepatitis B and Delta Screening, Prevention, and Linkage to Care among the PWUD Community in Philadelphia. Viruses 2024;16(4):628 View
  18. Khezri M, McKnight C, Weng C, Kimball S, Des Jarlais D, Katbi M. COVID-19 vaccination uptake and determinants of booster vaccination among persons who inject drugs in New York City. PLOS ONE 2024;19(5):e0303394 View